Soleus Capital Management L.P. Acquires 1,319,700 Shares of Celcuity Inc. (NASDAQ:CELC)

Soleus Capital Management L.P. grew its holdings in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 106.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,565,087 shares of the company's stock after purchasing an additional 1,319,700 shares during the period. Celcuity makes up 2.1% of Soleus Capital Management L.P.'s portfolio, making the stock its 14th biggest holding. Soleus Capital Management L.P. owned 6.91% of Celcuity worth $33,577,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Summit Investment Advisors Inc. boosted its position in shares of Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC bought a new position in shares of Celcuity during the 4th quarter valued at about $50,000. The Manufacturers Life Insurance Company bought a new position in shares of Celcuity during the 4th quarter valued at about $142,000. Bleakley Financial Group LLC bought a new position in shares of Celcuity during the 4th quarter valued at about $146,000. Finally, Trexquant Investment LP purchased a new stake in Celcuity during the fourth quarter valued at about $152,000. Institutional investors own 63.33% of the company's stock.

Celcuity Stock Down 2.9%

Shares of NASDAQ CELC traded down $0.31 during mid-day trading on Friday, reaching $10.44. The company had a trading volume of 144,757 shares, compared to its average volume of 298,558. The stock has a fifty day moving average of $10.19 and a two-hundred day moving average of $11.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The company has a market capitalization of $395.32 million, a price-to-earnings ratio of -4.00 and a beta of 0.56. Celcuity Inc. has a 12-month low of $7.58 and a 12-month high of $19.77.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. As a group, equities research analysts expect that Celcuity Inc. will post -2.62 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research note on Monday, May 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Celcuity in a research note on Thursday, May 15th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $30.80.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.